Ohio would see more than $1 billion in revenue if Medicaid expansion group stays, new study finds
A poll released Thursday, May 1 showed 76% of Americans oppose cuts to Medicaid. (Photo via Getty Images)
A new study of Ohio Medicaid showed the Affordable Care Act expansion group of nearly 770,000 would bring the state an economic benefit of $1 billion if it survives cuts at the federal and state level. But Ohio Republicans might include a trigger in the state budget to cut the expansion if Medicaid budget cuts come down from Congress.
The Ohio Senate is expected to release its proposed state operating budget in the next few days, a proposal that will then be compared to and combined with the Ohio House's version already passed last month, before a final draft heads to the governor for his signature.
The Ohio House's version of the budget absorbed a proposal by Gov. Mike DeWine in his executive budget that creates a trigger effect, eliminating Group VIII, or the Medicaid expansion eligibility group, 'if the federal government sets the federal medical assistance percentage below (its current level of) 90%,' according to budget documents.
Child health programs including even pediatric cancer research see cuts in Ohio House budget draft
The expansion group, which was introduced administratively in Ohio in 2014, represents adults aged 19 to 64 who earn less than 138% of the federal poverty level but aren't eligible for Medicaid in other categories. For a family of two, the poverty level stands at $21,150 in Ohio and other contiguous states.
The federal budget, which is being reviewed by the U.S. Senate, could include a larger state contribution to the Medicaid program than seen in the past, dropping the federal contribution, called the Federal Medical Assistance Percentage or FMAP, from its current share of 90%. If that is passed into law, and if the state budget is passed and signed with the trigger in place, the expansion population would face cuts.
According to the Health Policy Institute of Ohio's newest policy brief, written by Amy Rohling McGee, the 10% the state currently pays to support Medicaid stands in juxtaposition to revenue and state savings generated by the program.
After accounting for the savings the state nets as a part of the program and revenue created, researchers found that the state share is effectively 1.4%.
'Discontinuing expansion would save substantially less than the state share amount, it would reduce federal funds coming to Ohio by over $42 billion over five years, and would leave an estimated 435,000 Ohioans without coverage,' Rohling McGee wrote as part of the HPIO's 2025 Ohio Medicaid Expansion Study.
The economic activity that results from those in the Medicaid expansion group having their health insurance covered 'is projected to generate over $1.1 billion over the next five years in state general revenue from personal income taxes, sales taxes and gross receipts taxes,' according to HPIO researchers.
State revenue would drop in a number of other ways without the expansion group, according to the HPIO Medicaid study. The population brings state revenue through health insuring corporation (HIC) premium taxes and franchise fees, along with prescription drug rebates.
'As part of the federal Medicaid Drug Rebate Program, Ohio's Medicaid program receives rebates from drug manufacturers in exchange for the program's coverage of most of the manufacturer's drugs,' the HPIO wrote. 'These rebates offset the costs of most outpatient prescription drugs dispensed to Medicaid patients.'
Money the state receives from drug rebates goes back into the Medicaid budget to support spending, according to the study.
Along with drops in economic health for the state, the loss of the Medicaid expansion group could negatively impact the state's overall health, dropping the number of insured Ohioans. The institute's research said Ohio's uninsured rate 'would potentially increase by 80%' in fiscal year 2026 without the existence of Medicaid expansion.
Those in the expansion group can include students, Ohioans with chronic health conditions, and older residents. Almost 50% of the Ohioans covered under the Medicaid expansion are among the state's workforce, according to the Center for Community Solutions.
If the Medicaid expansion remained as it is now, the policy institute found Ohio would get more than $42 billion from the federal government over five years to fund the population in that expansion.
'The state would have to raise considerable revenue to be able to fill the gap that elimination of expansion would leave,' the study stated.
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Newsweek
27 minutes ago
- Newsweek
The 1600: America Doesn't Have a Conservative Party
The Insider's Track Good morning, I paid $8 for a black iced coffee yesterday in my neighborhood. Eight. Dollars. Sometimes I think most of the underlying rage you see bubbling up around the country can be attributed to this feeling of just being constantly ripped off wherever you go. Speaking of getting ripped off, Congress is in the process of stitching up the votes on President Trump's "Big Beautiful Bill" flagship legislation in hopes of getting it to his desk by the Fourth. Following a narrow 51–49 procedural vote over the weekend, the Senate advanced the bill to the debate stage, with Senators Rand Paul and Thom Tillis joining all Democrats in opposition. Targeted by MAGA for his disloyalty, Tillis immediately announced he's not running for re-election, thus putting NC potentially in play for Senate Dems next year (the modern GOP has no room for actual conservatives). So once the Senate passes the bill, it gets kicked back to the House as part of the reconciliation process before going to Trump. I'd put it at extremely likely that this giant turd of a bill becomes law in time for the fireworks on Friday. So what's in this thing? It's mostly an extension of the 2017 tax cuts, with some deep cuts to the welfare state for good measure. The current Senate version raises the debt ceiling $5 trillion. It'll increase the deficit by some $3 trillion over the next decade, per the Congressional Budget Office. (I've seen lots of Trump supporters attack the CBO for its scoring of this bill as some kind of "lefty" organization. Please. The CBO is run by a Bush appointee). The bill uses this well-worn accounting trick to make it look like Republicans are actually reducing the deficit by $508 billion, as Lindsey Graham falsely claimed over the weekend. But that's based on this little gimmick that lets them basically write off the $4 trillion cost of extending the tax cuts. So when you see Republicans tossing around that $508B number this week, it should immediately set off your B.S. detector. Here's some other random little tidbits that caught my eye in the current manifestation of the bill: A huge cut in SNAP benefits and food assistance for the poor, plus another $1 trillion in cuts to Medicaid, Medicare and Obamacare (but mostly Medicaid). Millions will probably lose their coverage. This is the provision that Dems could run with as a winning message for the midterms, if they aren't too busy fighting for trans girls in sports or whatever. A tax on remittances, which is the money that immigrants send home, has been watered down to effectively be meaningless. House Rs passed a 5% tax on remittance, which was cut to 3.5% by the Senate, and then further to 1%. It also doesn't apply to bank transfers. This is one of those things I don't understand. It's a tax on US dollars flowing out of the country. Who is the lobby pushing Senate Rs against this? Western Union? On the energy front, the bill phases out Biden's tax credits for solar and wind—not surprising—while adding an excise tax on new renewable projects that utilize components made in China. At the same time, there's provisions tucked in there to incentivize domestic coal production. Making Coal Great Again, baby. Our children will be ashamed of us. Thankfully, the bill no longer includes Sen. Mike Lee's provision to sell off millions of acres of pristine federal land in the West to developers after an outcry from (actual) conservative voters. Teddy Roosevelt would've been spinning in his grave. The bottom line is that this legislation acts as a giant wealth transfer from the poor to the rich and the young to the old. Younger earners get nothing from the tax cuts, which are all structured to benefit higher-earners. It adds trillions to the national debt, which means higher taxes and mortgage payments for young Americans trying to start or build their families. One nonpartisan analysis suggests a 40-year-old making the median income will lose $7,500 over their lifetime, while a 70-year-old with the same income nets $17,500. The Boomers win, as always. And then we wonder why young voters turn out in record numbers in our most expensive city to elect a socialist. If this is the alternative, why wouldn't they? If this whole charade does anything, it should finally disabuse Americans of this notion that modern-day Republicans are the conservative party. You simply cannot be an actual conservative while voting to increase the debt, adding to the deficit, all while doing precisely nothing to deal with our spending problem. The Rundown A fierce war of words has erupted between Iran's Supreme Leader Ali Khamenei and President Donald Trump following recent U.S. strikes on Iran's nuclear facilities. Khamenei accused Trump of "exaggerating in order to cover up and conceal the truth," directly responding to Trump's claim that the U.S. had "obliterated" Iran's nuclear sites. Separately, Trump said that he is offering Iran "nothing" and is refusing to engage with Iranian officials, signaling a hardening U.S. stance. Read more. Also happening: US-Canada trade talks: Canada and the United States have resumed trade negotiations after Canadian Prime Minister Mark Carney agreed to rescind the country's digital services tax on U.S. technology companies. The development follows President Donald Trump's announcement on Friday that he was suspending all trade talks with Canada "effective immediately" over the tax policy. Here's the latest. Week in review: President Donald Trump is coming off what may be his most successful week in office—a landmark Supreme Court ruling, a successful NATO summit, a ceasefire that appears to be holding in the Middle East, another peace deal in Africa, a stock market back to setting records and a key trade breakthrough with China. Read more. This is a preview of The 1600—Tap here to get this newsletter delivered straight to your inbox.
Yahoo
33 minutes ago
- Yahoo
Senate Republicans try to get Trump's tax cuts over the line, setting aside cost concerns
By Richard Cowan and Bo Erickson WASHINGTON (Reuters) -U.S. Senate Republicans on Monday will try to pass President Donald Trump's sweeping tax-cut and spending bill, despite divisions within the party about its expected $3.3 trillion hit to the nation's debt pile. They were set for a marathon session in which the minority Democrats are allowed to offer an unlimited number of votes, part of the arcane process Republicans are using to bypass Senate rules that normally require 60 of the chamber's 100 members to agree on legislation. The nonpartisan Congressional Budget Office released its assessment on Sunday of the bill's hit to the $36.2 trillion debt, figuring that it would add about $800 billion more than the version passed last month in the House of Representatives. Many Republicans dispute that claim, contending that extending existing policy will not add to the debt. Nonetheless, international bond investors see incentives to diversify out of the U.S. Treasury market. Democrats, meanwhile, hope the latest, eye-widening figure could stoke enough anxiety among fiscally minded conservatives to get them to buck their party, which controls both chambers of Congress. 'Republicans are doing something the Senate has never, never done before, deploying fake math and accounting gimmicks to hide the true cost of the bill," Democratic Senate Minority Leader Chuck Schumer said on Sunday. "Republicans are about to pass the single most expensive bill in U.S. history to give tax breaks to billionaires while taking away Medicaid, SNAP benefits and good-paying jobs for millions of people." The Senate narrowly advanced the tax-cut, immigration, border and military spending bill in a procedural vote late on Saturday, voting 51-49 to open debate on the 940-page megabill. One powerful illustration of the Republican divide came on Sunday when Senator Thom Tillis of North Carolina said he would not seek re-election, after Trump threatened to back a challenger to him in next year's midterm elections over his vote against the bill. Trump on social media has hailed the progress as a "great victory" for his "great, big, beautiful bill." In a separate post on Sunday, he said: "We will make it all up, times 10, with GROWTH, more than ever before." Trump wants the bill passed before the July 4 Independence Day holiday. While that deadline is one of choice, lawmakers will face a far more serious deadline later this summer when they must raise the nation's self-imposed debt ceiling or risk a devastating default. If the Senate succeeds in passing the bill, it will then go to the House, where members are also divided, with some angry about its cost and others worried about cuts to the Medicaid program. Republicans can afford to lose no more than three votes in either chamber to pass a bill the Democrats are united in opposition to. HITS TO BENEFITS The legislation was the sole focus of a marathon weekend congressional session marked by political drama, division and lengthy delays as Democrats seek to slow the legislation's path to passage. Senator Rand Paul of Kentucky, the other Republican "no" vote, opposed the legislation because it would raise the federal borrowing limit by an additional $5 trillion. The megabill would extend the 2017 tax cuts that were Trump's main legislative achievement during his first term as president, cut other taxes and boost spending on the military and border security. Senate Republicans, who reject the CBO's estimates on the cost of the legislation, are set on using an alternative calculation method that does not factor in costs from extending the 2017 tax cuts. Outside tax experts, like Andrew Lautz from the nonpartisan think tank Bipartisan Policy Center, call it a "magic trick." Using this calculation method, the Senate Republicans' budget bill appears to cost substantially less and seems to save $500 billion, according to the BPC analysis. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Miami Herald
33 minutes ago
- Miami Herald
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%. "Today's strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna. "An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines." In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1] According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3] P304 ( NCT06602024 ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest. Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's engagement with regulators on filing submissions for its standalone flu vaccine candidate; and the efficacy, safety and tolerability of mRNA-1010. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at . Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris RidleyHead of Global Media Relations+1 Investors: Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc.